

ANSWER 1 OF 1 JAPIO (C) 2005 JPO on STN.  
AN 2000-290197 JAPIO  
TI COMPOSITION CONTAINING **MULTIFUNCTIONAL PROTEASE  
INHIBITOR AS ACTIVE INGREDIENT**  
IN IQBAL MOHAMED; DIEBOLD JAMES; SIMAN ROBERT; CHATTERJEE SANKAR; KAUER JAMES  
C  
PA CEPHALON INC  
PI JP 2000290197 A 20001017 Heisei  
AI JP 2000-2705 (JP20000002705 Heisei) 19951114  
PRAI US 1994-337795 19941114  
US 1995-464398 19950605  
US 1995-552794 19951103  
SO PATENT ABSTRACTS OF JAPAN (CD-ROM), Unexamined Applications, Vol. 2000

*Also caplus, medline, cancerlit & Biocng.*

ANSWER 1 OF 1 USPATFULL on STN  
AN 2005:99056 USPATFULL  
TI Methods of protein production in yeast  
IN Barr, Philip J., Oakland, CA, UNITED STATES  
Gibson, Helen L., Oakland, CA, UNITED STATES  
PI US 2005084972 A1 20050421  
AI US 2004-914863 A1 20040809 (10)  
PRAI US 2003-493984P 20030808 (60)  
DT Utility  
FS APPLICATION  
LREP Daniel M. Becker, c/o HELLER EHRMAN WHITE & MCAULIFFE LLP, 275  
Middlefield Road, Menlo Park, CA, 94025, US  
CLMN Number of Claims: 32  
ECL Exemplary Claim: 1  
DRWN 1 Drawing Page(s)  
LN.CNT 2396

(FILE 'HOME' ENTERED AT 17:38:49 ON 17 AUG 2005)

FILE 'USPATFULL, JAPIO, EPFULL, PCTFULL, BIOENG' ENTERED AT 17:39:43 ON  
17 AUG 2005

L1 1 S MULTIFUNCTIONAL PROTEASE INHIBITOR  
L2 0 S L1 (A) SECRETORY LEUCOCYTE PROTEASE  
L3 1 S FUSION PROTEIN (A) ALPHA 1-ANTITRYPSIN  
L4 0 S FUSION PROTEIN (A) SECRETORY LEUCOCYTE PROTEASE INHIBITOR  
L5 0 S FUSION PROTEIN (A) SLPI  
L6 0 S FUSION PROTEASE INHIBITOR  
L7 0 S FUSION (A) SERPIN  
L8 0 S MULTIFUNCTIONAL SERINE PROTEASE INHIBITOR  
L9 0 S MULTIFUNCTIONAL SERINE PROTEASE INHIBITOR  
L10 1 S HYBRID PROTEASE INHIBITOR  
L11 5185 S ALPHA 1-ANTITRYPSIN  
L12 1 S L11 (A) FUSION PROTEIN  
L13 13 S L11 (A) SLPI  
L14 0 S L13 (A) FUSION  
L15 1 S HYBRID SERPIN  
L16 0 S SERPIN (A) FUSION PROTEIN  
L17 0 S ALPHA 1-ANITRYPSIN (A) SLPI  
L18 0 S ALPHA 1-ANITRYPSIN (A) TISSUE INHIBITOR  
L19 0 S ALPHA 1-ANITRYPSIN (A) TISSUE METALLOPROTEASE INHIBITOR  
L20 0 S HYBRID METALLOPROTEASE INHIBITOR  
L21 0 S FUSION PROTEIN (A) METALLOPROTEASE INHIBITOR

FILE 'BIOENG' ENTERED AT 18:07:33 ON 17 AUG 2005

L22 0 S MULTIFUNCTIONAL PROTEASE INHIBITOR  
L23 0 S FUSION PROTEASE INHIBITOR  
L24 0 S FUSION PROTEIN (A) PROTEASE INHIBITOR  
L25 0 S FUSION SERPIN  
L26 380 S PROTEASE INHIBITOR  
L27 0 S L6 (A) FUSION PROTEIN  
L28 0 S L6 (A) HYBRID  
L29 141 S L11  
L30 0 S L21  
L31 0 S L20  
L32 0 S L19  
L33 0 S L18  
L34 0 S L17  
L35 0 S L16  
L36 0 S L15  
L37 0 S L14  
L38 0 S L13  
L39 0 S L12  
L40 141 S L11  
L41 0 S L40 (A) FUSION PROTEIN

ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:898699 CAPLUS

DN 141:374746

TI Modified procollagen  $\alpha$  chain fusion protein and their uses in wound healing and fibrosis therapy

IN Kadler, Karl; Bulleid, Neil; Ashcroft, Gillian

PA The Victoria University of Manchester, UK

SO Brit. UK Pat. Appl., 59 pp.

CODEN: BAXXDU

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 2400852	A1	20041027	GB 2003-24457	20031021
	WO 2004094472	A2	20041104	WO 2004-GB1719	20040421
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				
	CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				
	GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				
	LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,				
	NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,				
	TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,				
	BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,				
	ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,				
	SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,				
	TD, TG				

PRAI GB 2003-9064 A 20030422

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1991:402499 CAPLUS  
 DN 115:2499  
 ED Entered STN: 12 Jul 1991  
 TI Recombinant **hybrid protease inhibitors** and  
 their use  
 IN Ringe, Dagmar  
 PA Massachusetts Institute of Technology, USA  
 SO PCT Int. Appl., 57 pp.  
 CODEN: PIXXD2

DT Patent  
 LA English  
 IC ICM C12N015-62  
 ICS C12N015-15; C12P021-02; C07K007-00  
 CC 3-4 (Biochemical Genetics)  
 Section cross-reference(s): 7

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9100912	A1	19910124	WO 1990-US3769	19900703
	W: CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE				
PRAI	US 1989-376876	A	19890707		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 9100912	ICM	C12N015-62
	ICS	C12N015-15; C12P021-02; C07K007-00

AB A highly specific hybrid protease inhibitor comprises a nonimmunogenic carrier polypeptide having an internal portion replaced/expanded with a synthetic peptide that specifically binds and inhibits a protease. The hybrid protease inhibitor also exhibits longer in vivo half-life than the synthetic peptide per se, which is desirable for clin. applications. Preparation of **hybrid protease inhibitors** that are inhibitory to elastase, chymotrypsin, trypsin, HIV protease, thrombin, and renin, resp., using interleukin-1  $\beta$  as a nonimmunogenic carrier polypeptide are demonstrated.

ST recombinant hybrid protease inhibitor interleukin; elastase inhibitor recombinant hybrid; trypsin inhibitor recombinant hybrid; chymotrypsin inhibitor recombinant hybrid; HIV protease inhibitor recombinant hybrid; thrombin inhibitor recombinant hybrid; renin inhibitor recombinant hybrid

IT Escherichia coli  
 (expression in, of hybrid protease inhibitor genes encoding interleukin 1- $\beta$ -synthetic peptide fusion)

IT Molecular cloning  
 (of hybrid nonimmunogenic protease inhibitor genes, in Escherichia coli)

IT Virus, animal  
 (human immunodeficiency, protease of, hybrid inhibitor containing interleukin 1- $\beta$  and synthetic inhibition site for inhibition of)

IT Lymphokines and Cytokines  
 RL: BIOL (Biological study)  
 (interleukin 1 $\beta$ , hybrid protease inhibitor containing, as nonimmunogenic carrier)

IT 118071-38-8 118102-43-5 134371-49-6  
 RL: PRP (Properties)  
 (HIV protease recognition and inhibition site, synthetic, hybrid inhibitor containing interleukin 1- $\beta$  and)

IT 134371-46-3  
 RL: PRP (Properties)  
 (chymotrypsin recognition and inhibition site, synthetic, hybrid inhibitor containing interleukin-1 $\beta$  and)

IT 133793-06-3 134371-48-5  
 RL: PRP (Properties)  
 (elastase recognition and inhibition site, synthetic, hybrid inhibitor  
 containing interleukin 1- $\beta$  and)

IT 9002-04-4, Thrombin 9002-07-7, Trypsin 9004-06-2, Elastase  
 9004-07-3, Chymotrypsin 9015-94-5, Renin, biological studies  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (inhibitor, interleukin 1- $\beta$  nonimmunogenic carrier-synthetic  
 peptide fusion as)

IT 37205-61-1, Protease inhibitor  
 RL: PRP (Properties)  
 (interleukin 1- $\beta$  nonimmunogenic carrier-synthetic peptide fusion  
 as, recombinant)

IT 75645-19-1 82252-55-9 134371-51-0 134371-52-1  
 RL: PRP (Properties)  
 (renin recognition and inhibition site, synthetic, hybrid inhibitor  
 containing interleukin 1- $\beta$  and)

IT 134371-50-9  
 RL: PRP (Properties)  
 (thrombin recognition and inhibition site, synthetic, hybrid inhibitor  
 containing interleukin 1- $\beta$  and)

IT 134371-47-4  
 RL: PRP (Properties)  
 (trypsin recognition and inhibition site, synthetic, hybrid inhibitor  
 containing interleukin 1- $\beta$  and)

=>